These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 26839079)

  • 1. Expression and purification of an engineered, yeast-expressed Leishmania donovani nucleoside hydrolase with immunogenic properties.
    Hudspeth EM; Wang Q; Seid CA; Hammond M; Wei J; Liu Z; Zhan B; Pollet J; Heffernan MJ; McAtee CP; Engler DA; Matsunami RK; Strych U; Asojo OA; Hotez PJ; Bottazzi ME
    Hum Vaccin Immunother; 2016 Jul; 12(7):1707-20. PubMed ID: 26839079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression, purification, immunogenicity and protective efficacy of a recombinant nucleoside hydrolase from Leishmania donovani, a vaccine candidate for preventing cutaneous leishmaniasis.
    McAtee CP; Seid CA; Hammond M; Hudspeth E; Keegan BP; Liu Z; Wei J; Zhan B; Arjona-Sabido R; Cruz-Chan V; Dumonteil E; Hotez PJ; Bottazzi ME
    Protein Expr Purif; 2017 Feb; 130():129-136. PubMed ID: 27773761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serodiagnostic and immunoprophylactic potential of a 78kDa protein of Leishmania donovani of Indian origin.
    Mukherjee M; Bhattacharyya A; Duttagupta S
    Med Sci Monit; 2002 Apr; 8(4):BR117-22. PubMed ID: 11951057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3M-052 as an adjuvant for a PLGA microparticle-based Leishmania donovani recombinant protein vaccine.
    Wang Q; Barry MA; Seid CA; Hudspeth EM; McAtee CP; Heffernan MJ
    J Biomed Mater Res B Appl Biomater; 2018 May; 106(4):1587-1594. PubMed ID: 28804955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A nonspecific nucleoside hydrolase from Leishmania donovani: implications for purine salvage by the parasite.
    Cui L; Rajasekariah GR; Martin SK
    Gene; 2001 Dec; 280(1-2):153-62. PubMed ID: 11738828
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leishmania donovani recombinant iron superoxide dismutase B1 protein in the presence of TLR-based adjuvants induces partial protection of BALB/c mice against Leishmania major infection.
    Daifalla NS; Bayih AG; Gedamu L
    Exp Parasitol; 2012 Jul; 131(3):317-24. PubMed ID: 22580023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive immunity against Leishmania nucleoside hydrolase maps its c-terminal domain as the target of the CD4+ T cell-driven protective response.
    Nico D; Claser C; Borja-Cabrera GP; Travassos LR; Palatnik M; Soares IS; Rodrigues MM; Palatnik-de-Sousa CB
    PLoS Negl Trop Dis; 2010 Nov; 4(11):e866. PubMed ID: 21085470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting kala-azar disease manifestations in asymptomatic patients with latent Leishmania donovani infection by detection of antibody against recombinant K39 antigen.
    Singh S; Kumari V; Singh N
    Clin Diagn Lab Immunol; 2002 May; 9(3):568-72. PubMed ID: 11986261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy.
    Ravindran R; Anam K; Bairagi BC; Saha B; Pramanik N; Guha SK; Goswami RP; Banerjee D; Ali N
    Infect Immun; 2004 Feb; 72(2):863-70. PubMed ID: 14742530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against Leishmania chagasi and Leishmania amazonensis experimental infections.
    Zanin FH; Coelho EA; Tavares CA; Marques-da-Silva EA; Silva Costa MM; Rezende SA; Gazzinelli RT; Fernandes AP
    Microbes Infect; 2007 Jul; 9(9):1070-7. PubMed ID: 17644455
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune responses induced by the Leishmania (Leishmania) donovani A2 antigen, but not by the LACK antigen, are protective against experimental Leishmania (Leishmania) amazonensis infection.
    Coelho EA; Tavares CA; Carvalho FA; Chaves KF; Teixeira KN; Rodrigues RC; Charest H; Matlashewski G; Gazzinelli RT; Fernandes AP
    Infect Immun; 2003 Jul; 71(7):3988-94. PubMed ID: 12819086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction and analysis of promiscuous T cell-epitopes derived from the vaccine candidate antigens of Leishmania donovani binding to MHC class-II alleles using in silico approach.
    Kashyap M; Jaiswal V; Farooq U
    Infect Genet Evol; 2017 Sep; 53():107-115. PubMed ID: 28549876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative assessment of a DNA and protein Leishmania donovani gamma glutamyl cysteine synthetase vaccine to cross-protect against murine cutaneous leishmaniasis caused by L. major or L. mexicana infection.
    Campbell SA; Alawa J; Doro B; Henriquez FL; Roberts CW; Nok A; Alawa CB; Alsaadi M; Mullen AB; Carter KC
    Vaccine; 2012 Feb; 30(7):1357-63. PubMed ID: 22210224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinesin motor domain of Leishmania donovani as a future vaccine candidate.
    Dey A; Sharma P; Redhu NS; Singh S
    Clin Vaccine Immunol; 2008 May; 15(5):836-42. PubMed ID: 18353921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nucleoside hydrolase from Leishmania (L.) donovani is an antigen diagnostic for visceral leishmaniasis.
    Santana DM; Borja-Cabrera GP; Paraguai de Souza E; Sturm NR; Palatnik de Sousa CB; Campbell DA
    Mol Biochem Parasitol; 2002 Apr; 120(2):315-9. PubMed ID: 11897139
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunotherapy against visceral leishmaniasis with the nucleoside hydrolase-DNA vaccine of Leishmania donovani.
    Gamboa-León R; Paraguai de Souza E; Borja-Cabrera GP; Santos FN; Myashiro LM; Pinheiro RO; Dumonteil E; Palatnik-de-Sousa CB
    Vaccine; 2006 May; 24(22):4863-73. PubMed ID: 16635538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and cellular immune responses to glucose regulated protein 78 -- a novel Leishmania donovani antigen.
    Jensen AT; Ismail A; Gaafar A; El Hassan AM; Theander TG
    Trop Med Int Health; 2002 May; 7(5):471-6. PubMed ID: 12000658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leishmania promastigote membrane antigen-based enzyme-linked immunosorbent assay and immunoblotting for differential diagnosis of Indian post-kala-azar dermal leishmaniasis.
    Saha S; Mazumdar T; Anam K; Ravindran R; Bairagi B; Saha B; Goswami R; Pramanik N; Guha SK; Kar S; Banerjee D; Ali N
    J Clin Microbiol; 2005 Mar; 43(3):1269-77. PubMed ID: 15750095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis.
    Stäger S; Smith DF; Kaye PM
    J Immunol; 2000 Dec; 165(12):7064-71. PubMed ID: 11120835
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.